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Background. It is important to know the reliability of early
changes in proteinuria in predicting late renal outcomes. The
IDNT was a trial in which treatment assignment, baseline
and follow-up blood pressure determinations, and albumin/
creatinine ratios (ACR), and renal outcomes were recorded.
Methods. Risk of renal outcomes in the IDNT was assessed
by proportional hazards modeling as a function of treatment
assignment, and achieved systolic blood pressure (SBP) both
without, and then with, inclusion of values for baseline protein-
uria and early changes in proteinuria.
Results. In models without ACR variables, both treatment
with irbesartan and achieved SBP during follow-up were sig-
nificantly predictive of the risk of renal outcomes. Addition of
ACR variables to the models reduced the apparent impact of
assignment to irbesartan by 52% to 81%, and irbesartan was
no longer a significant predictor of renal outcomes. Conversely,
addition of ACR variables to the models attenuated the effect
of achieved follow-up SBP by only 32% to 46%, and follow-up
BP remained a highly significant predictor of renal outcomes.
Conclusion. The ability of early changes in proteinuria to
predict the impact of treatment on renal outcomes is a func-
tion of the specific treatment. One must use caution in using
early changes in proteinuria as a surrogate for longer-term renal
outcomes.
The Irbesartan Diabetic Nephropathy Trial (IDNT)
was a multinational, multicenter, randomized, double-
blinded, placebo-controlled trial designed to determine
the impact of treatment with the angiotensin II recep-
tor blocker irbesartan (compared with amlodipine and
placebo) on renal and cardiovascular outcomes in pa-
tients with type 2 diabetic nephropathy. The methods
and major renal and cardiovascular outcomes have been
reported [1–3]. We have previously reported that both
treatment with irbesartan and achievement of a lower
follow-up systolic blood pressure (SBP) were indepen-
dently associated with improved renal outcomes [2, 4].
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We have also reported that both irbesartan treatment and
lower blood pressure were associated with a reduction in
proteinuria [5]. The present paper examines the extent
with which the beneficial effects of irbesartan treatment
and lower achieved SBP were correlated, and could be
predicted by, their effects to reduce proteinuria.
METHODS
The general methods of the IDNT and the methods
for ascertaining outcomes have previously been detailed
[1, 2]. For the purposes of this study, a renal outcome
was the composite of either doubling of serum creati-
nine or development of end-stage renal disease (ESRD),
which ever was earlier. Blood pressure was measured
twice prior to randomization and at quarterly visits there-
after. Blood pressure declined on average by 15 mm Hg
from baseline to six months, and was fairly stable there-
after. Therefore, mean follow-up SBP was defined as the
mean of values obtained at all quarterly study visits on or
after six months. Twenty-four–hour urines were collected
twice during baseline, at three and six months, and ev-
ery six months thereafter. Albumin and creatinine values
were determined centrally. An albumin/creatinine ratio
(ACR) was computed from these 24-hour urines. The val-
ues for the ACR were log transformed to approximate a
normal distribution. Among patients assigned to irbesar-
tan, proteinuria declined sharply over the first three to
six months [5], whereas proteinuria among patients as-
signed to amlodipine or placebo changed little. After six
months, proteinuria in all groups declined slowly for the
remainder of the study. Therefore, average follow-up pro-
teinuria was defined as the mean of the log-transformed
ACR from six months to the end of the study. The impact
of treatment assignment and of baseline and mean follow-
up SBP and ACR on patients with renal survival for at
least six months was determined by proportional hazards
analysis of the time to the composite renal outcome, as
defined above.
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Table 1. Impact of various factors on risk of a renal event in the
IDNT
Factor Relative risk 95% CI P value
Model 1
Irb vs. Aml or Plac 0.69 0.56–0.85 0.0007
15 mm lower fu SBP 0.63 0.56–0.70 <0.0001
Model 2
Baseline log2(ACR)a 3.15 2.79–3.85 <0.0001
 log2(ACR) B-6mob 0.41 0.36–0.47 <0.0001
Model 3
Irb vs. Aml or Plac 0.85 0.68–1.07 0.17
15 mm lower fu SBP 0.80 0.72–0.90 0.0001
Baseline log2(ACR)a 3.07 2.71–3.47 <0.0001
 log2(ACR) B-6mob 0.42 0.37–0.49 <0.0001
aFor each doubling of ACR.
bFor each halving of ACR.
RESULTS
We have previously reported that treatment with irbe-
sartan (compared with either amlodipine or placebo) and
a lower follow-up SBP were independently significantly
associated with an improved renal outcome [4]. These
effects are listed as Model 1 in Table 1. We have also pre-
viously reported that both baseline proteinuria and the
change in proteinuria during follow-up are strong inde-
pendent predictors of the renal outcome [5]. These effects
are listed as Model 2 in Table 1. Finally, we have reported
that both treatment with irbesartan and a lower achieved
SBP independently reduced the ACR [5]. Treatment with
irbesartan led to a 47% (95%CI 39–53, P < 0.0001) re-
duction of follow-up ACR compared with amlodipine or
placebo, while a 15 mm Hg lower follow-up SBP was asso-
ciated with a 18% (95%CI 12–23, P < 0.0001) reduction
in the ACR.
Since treatment with irbesartan and a lower achieved
follow-up SBP both lower proteinuria and protect against
the renal end point, it is of interest to see whether
the effects of either treatment with irbesartan or lower
achieved SBP can be “explained” by the reduction in
ACR. This can be tested by putting all four factors into the
same renal survival model. The results of this analysis are
shown as Model 3 in Table 1. It can be seen in this model
that addition of treatment and follow-up blood pressure
has very little effect on the impacts of baseline and follow-
up changes in ACR, but that inclusion of the ACR vari-
ables attenuates the impact of treatment by 52%, and
of achieved SBP by 46%. Treatment with irbesartan is
no longer a significant predictor of outcomes, but lower
SBP remains highly significantly associated with a bet-
ter renal outcome, independent of the ACR variables. If
one includes three-month values for proteinuria and SBP
into the models, the impact of irbesartan treatment (RR
0.94, 95%CI 0.74–1.19, P = 0.61) is further attenuated
to 19% of its value prior to adjustment for proteinuria,
while the impact of follow-up SBP (RR/15 mm Hg 0.75;
95%CI 0.67–0.85, P < 0.0001) is restored to 68% of its
value prior to adjustment for proteinuria.
DISCUSSION
There remains controversy about the extent to which
early changes in proteinuria predict reliably the long-
term impacts of interventions to preserve renal function
in renal disease. It is clear that initial proteinuria is a
strong predictor of renal outcomes, and that early reduc-
tions in proteinuria generally indicate an improvement in
outcomes. The results of the analyses above are consistent
with many other reports, including several in this supple-
ment, suggesting that the beneficial impact of blockade
of the renin-angiotensin-aldosterone system (RAAS), as
by an agent such as irbesartan, is strongly correlated with
early changes in proteinuria. But this relationship may
not hold for other interventions. Specifically, the benefi-
cial impact of blood pressure reduction is not closely cor-
related with early reductions in proteinuria. The above
results show that a lower achieved SBP during follow-up
remains an important and highly significant predictor of
renal outcomes, independent of baseline and follow-up
proteinuria. These results are consistent with an analysis
from the Modification of Diet in Renal Disease Study,
showing that early changes in proteinuria accounted for
only about 20% of the impact of random assignment to
the lower blood pressure group [6]. Conversely, the re-
sults of the African American Study of Kidney Disease
[7] have shown that assignment to the lower blood pres-
sure arm of the study, though associated with a significant
reduction in proteinuria, was associated with no protec-
tion against the renal outcomes. This would seem to im-
ply that one should use considerable caution in assuming
that early changes in proteinuria will reliably predict the
later outcomes of interventions, at least those other than
RAAS blockade.
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